See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Rongqin Zheng
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: To obtain high yield histological samples by targeted PCa biopsy is the current trend compared of transrectal ultrasound (TRUS) guided systematic histological biopsy which is regarded as golden standard for prostate cancer (PCa) diagnosis. In this paper, we present a targeted PCa imaging strategy using real-time molecular photoacoustic imaging system integrated with handheld US probe (PAI/US) and synthesized integrin αvβ3 targeted probe based on ICG (cRGD–ICG). Results: A small molecular PAI probe was synthesized and proved excellent targeted imaging ability in vitro. In vivo photoacoustic imaging was carried out after intravenous injection of cRGD-ICG in orthotopic PCa bearing beard rats under facilitation of PAI/US system. Maximum molecular photoacoustic signals were observed in the tumor area in vivo post probe injection, which showed 3.8 folds higher signal enhancement than in the control group (P < 0.05, respectively). Significant higher cRGD-ICG accumulation was observed under confocal microscopy in tumor region rather than normal prostate tissue. Conclusions: All our results showed that the comprehensive strategy provided a high-yield and reliable method for PCa diagnosis and targeted prostate biopsy, with great clinical transforming potential.
Keywords
Prostate cancer, Photoacoustic imaging, Targeted biopsy, Molecular imaging
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Editorial decision: Accept
On 27 Mar, 2020
Editor assigned
On 26 Mar, 2020
Submission checks complete
On 25 Mar, 2020
Editor invited
On 25 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 23 Mar, 2020
Editor assigned
On 19 Mar, 2020
Submission checks complete
On 18 Mar, 2020
Editor invited
On 18 Mar, 2020
Version 1
Posted 11 Dec, 2019
No comments provided
Editorial decision: Major revision
On 25 Feb, 2020
Review #1 received
Received 21 Feb, 2020
Review #2 received
Received 19 Feb, 2020
Reviewer #2 agreed
On 07 Feb, 2020
Reviewer #1 agreed
On 05 Feb, 2020
Reviewers invited
Invitations sent on 19 Dec, 2019
Editor assigned
On 17 Dec, 2019
Submission checks complete
On 10 Dec, 2019
Editor invited
On 10 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Rongqin Zheng
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
No community comments so far
Editorial decision: Accept
On 27 Mar, 2020
Editor assigned
On 26 Mar, 2020
Submission checks complete
On 25 Mar, 2020
Editor invited
On 25 Mar, 2020
No comments provided
Editorial decision: Minor revision
On 23 Mar, 2020
Editor assigned
On 19 Mar, 2020
Submission checks complete
On 18 Mar, 2020
Editor invited
On 18 Mar, 2020
Version 1
Posted 11 Dec, 2019
No comments provided
Editorial decision: Major revision
On 25 Feb, 2020
Review #1 received
Received 21 Feb, 2020
Review #2 received
Received 19 Feb, 2020
Reviewer #2 agreed
On 07 Feb, 2020
Reviewer #1 agreed
On 05 Feb, 2020
Reviewers invited
Invitations sent on 19 Dec, 2019
Editor assigned
On 17 Dec, 2019
Submission checks complete
On 10 Dec, 2019
Editor invited
On 10 Dec, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: To obtain high yield histological samples by targeted PCa biopsy is the current trend compared of transrectal ultrasound (TRUS) guided systematic histological biopsy which is regarded as golden standard for prostate cancer (PCa) diagnosis. In this paper, we present a targeted PCa imaging strategy using real-time molecular photoacoustic imaging system integrated with handheld US probe (PAI/US) and synthesized integrin αvβ3 targeted probe based on ICG (cRGD–ICG). Results: A small molecular PAI probe was synthesized and proved excellent targeted imaging ability in vitro. In vivo photoacoustic imaging was carried out after intravenous injection of cRGD-ICG in orthotopic PCa bearing beard rats under facilitation of PAI/US system. Maximum molecular photoacoustic signals were observed in the tumor area in vivo post probe injection, which showed 3.8 folds higher signal enhancement than in the control group (P < 0.05, respectively). Significant higher cRGD-ICG accumulation was observed under confocal microscopy in tumor region rather than normal prostate tissue. Conclusions: All our results showed that the comprehensive strategy provided a high-yield and reliable method for PCa diagnosis and targeted prostate biopsy, with great clinical transforming potential.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...